BioCentury | Jun 3, 2020

Third Rock-launched Pliant is latest biotech to climb on public debut

Pliant joins a slew of recent biotechs that have seen substantial first-day gains. The fibrosis company closed up $5.30 (33%) to $21.30 on Wednesday after raising $144 million through the sale of 9 million shares...
BioCentury | Mar 3, 2020

Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round

A $100 million series C round led by Novartis and backed by multiple crossover investors gives Third Rock-founded Pliant ample cash to push forward with multiple fibrosis programs. The cash bolus comes less than half...
BioCentury | Oct 23, 2019
Company News

Pliant to flesh out fibrosis pipeline after NASH deal with Novartis

Pliant’s deal to out-license its NASH candidate to Novartis for $80 million will allow the fibrosis company to fund development of its lead candidate, as well as advance its preclinical pipeline. Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Sep 17, 2019
Clinical News

Biogen stops Phase II for returned IPF candidate

Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns. Biogen Inc. (NASDAQ:BIIB) had licensed the humanized mAb against...
BioCentury | Sep 13, 2019
Distillery Therapeutics

Peptide-macrocycle conjugates for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Hydroquinone macrocycle-peptide conjugates targeting CD51/CD61 could treat breast cancer by trapping polyamines, which promote cell proliferation and differentiation. The conjugates consist of pillararenes attached to the peptide sequence arginine-glycine-aspartate...
BioCentury | Sep 5, 2019
Preclinical News

2016 study on gut integrin HIV target can't be replicated

Three preclinical studies and one clinical trial could not replicate the antiviral effects of an antibody against α4β7 to treat HIV or simian immunodeficiency virus, casting doubt on a theory that preventing CD4+ T cells...
BioCentury | Nov 26, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
BioCentury | Nov 2, 2018
Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
BioCentury | Sep 28, 2018

Morphic reloads

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace. Existing investor Omega Funds and new investor Novo Holdings...
BioCentury | Sep 25, 2018
Financial News

Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors...
Items per page:
1 - 10 of 314